AstraZeneca Pharmaceuticals LP v. Sun Pharmaceutical Industries Ltd.
1:07-cv-00806
Overview
Parties
Movant
AstraZeneca Pharmaceuticals LP NPE (Individual / Inventor)
Represented By
9 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Defendant
Caraco Pharmaceutical Laboratories Ltd. Operating Company
Represented By
0 Attorneys ListedSun Pharmaceutical Industries Inc. Operating Company
Represented By
0 Attorneys ListedSun Pharmaceutical Industries Ltd. Operating Company
Represented By
5 Attorneys ListedAbrams & Bayliss LLP
20 Montchanin Road, Suite 200
Plaintiff
Shionogi Seiyaku Kabushiki Kaisha Operating Company
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
IPR Pharmaceuticals Inc. Operating Company
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
AstraZeneca UK Limited NPE (University / Research)
Represented By
2 Attorneys ListedWomble Carlyle Sandridge Rice
Womble Carlyle Sandridge Rice, 222 Delaware Avenue
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° RadarMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
No Co-Pending Disputes Detected in Current Index
There are no other active filings for this patent family across our indexed PTAB, U.S. Court, UPC, or EPO databases.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
USRE37314
Pyrimidine derivatives
|
Filed: 1998-08-27
Issued: 2001-08-07
|
Expired (Term Ended)
Expires: 2016-01-08
|
Patent Enforceability & Injunction Risk Assessment
Statutorily Barred — Patent expired. Under 35 U.S.C. § 283, courts cannot grant an injunction once a patent's term concludes. Litigation is restricted exclusively to past damages lookback.
Standard Statutory Term — No obviousness-type double patenting truncation noted.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
73
Dispositive
35
Granted
6
Denied
2
Pending / Review
45
Motions by Category
Key Dispositive Motions & Rulings